Poly-MxB

Poly-MxB

polymyxin b

Manufacturer:

Bharat Serums & Vaccines

Distributor:

Pahang Pharmacy
Concise Prescribing Info
Contents
Polymyxin B sulfate
Indications/Uses
Acute infections caused by susceptible strains of Pseudomonas aeruginosa eg, UTI, meninges & blood stream infections. Serious infections caused by H influenzae specifically meningeal infections (intrathecal route only), E coli specifically UTI, Aerobacter aerogenes & Klebsiella pneumoniae specifically bacteremia, when less potentially toxic drugs are ineffective or contraindicated.
Dosage/Direction for Use
IV Adult & childn 15,000-25,000 u/kg daily every 12 hr. Infant Up to 40,000 u/kg daily. Renal impairment Reduce from 15,000 u/kg downward every 12 hr. Total daily dose: Not to exceed 25,000 u/kg daily. IM Adult & childn 25,000-30,000 u/kg daily divided at 4-6 hr intervals. Infant Up to 40,000 u/kg daily. Intrathecal Adult & childn >2 yr 50,000 u once daily for 3-4 days then 50,000 u once every other day for at least 2 wk after cultures of CSF are -ve & sugar content returned to normal. Childn <2 yr 20,000 u once daily for 3-4 days or 25,000 u once every other day. Continue 25,000 u once every other day for at least 2 wk after cultures of CSF are -ve & sugar content returned to normal.
Contraindications
Special Precautions
Administer IM &/or intrathecal in hospitalized patients only. Discontinue use if diminishing urine output, rising BUN, signs of resp paralysis occur. Overgrowth of nonsusceptible organisms including fungi; superinfection. Perform baseline renal function & monitor blood levels prior to therapy. Avoid concurrent use of curariform muscle relaxant & other neurotoxic drugs eg, ether, tubocurarine, succinylcholine, gallamine, decamethonium, Na citrate. Renal impairment &/or nephrotoxicity. Pregnancy & lactation.
Adverse Reactions
Albuminuria, cylindruria, azotemia, rising serum drug levels, facial flushing, dizziness progressing to ataxia, drowsiness, circumoral & stocking-glove peripheral paresthesias, apnea, signs of meningeal irritation. Drug fever, urticarial rash, skin hyperpigmentation, severe pain at IM inj site, thrombophlebitis at IV inj site.
Drug Interactions
Increased nephrotoxicity & neurotoxicity w/ aminoglycosides. Potentiated neuromuscular blockade development w/ curariform muscle relaxant & other neurotoxic drugs eg, ether, tubocurarine, succinylcholine, gallamine, decamethonium, Na citrate. Enhanced nephrotoxicity w/ Na cephalothin & colistin. Transganglionic degenerative atrophy w/ glutamic acid.
MIMS Class
Other Antibiotics
ATC Classification
J01XB02 - polymyxin B ; Belongs to the class of polymyxins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Poly-MxB powd for inj 500,000 units
Packing/Price
(lyo) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in